Trisalus Life Sciences, INC Form 4 insider transactions

TriSalus Life Sciences, Inc. reports a transaction where Chief Financial Officer David Patience acquired shares through a tax withholding arrangement.

Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., acquired 3,990 shares through the company's Employee Stock Purchase Plan.

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, Inc., acquired 561 shares of common stock through the Employee Stock Purchase Plan.

TriSalus Life Sciences, Inc. reports a significant stock grant and option award to Chief Medical Officer Richard Henry Marshall.

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, Inc., reported a sale of 543 common shares on May 15, 2026, for tax withholding purposes.

Mats Wahlstrom, a Director at TriSalus Life Sciences, Inc., reported the acquisition of 60,000 common shares.

Michael P. Stansky, a Director at TriSalus Life Sciences, Inc., has acquired a significant number of common shares, increasing his beneficial ownership.

Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., acquired 39,682 shares of common stock.

David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc., reported the acquisition of 7,100 shares of common stock.

Director Gary B. Gordon acquired 10,000 shares of common stock in TriSalus Life Sciences, Inc. on May 15, 2026.

Director Kerry R. Hicks acquired 28,201 restricted stock units and 56,403 stock options in TriSalus Life Sciences, Inc.

Director Mats Wahlstrom was granted restricted stock units and stock options as part of his 2026 board compensation package.

Director William Valle acquired 52,754 restricted stock units and 56,403 stock options in TriSalus Life Sciences.

Director Michael Stansky acquired 43,590 restricted stock units and 47,003 stock options in TriSalus Life Sciences.

Frankenius Equity AB converted 230,000 shares of Series A Convertible Preferred Stock into 759,000 shares of TriSalus Life Sciences common stock.

TriSalus Life Sciences Director David J. Matlin converted 100,000 shares of Series A Preferred Stock into 330,000 shares of Common Stock.

TriSalus Life Sciences' Chief of Clinical Operations, Jodi Devlin, sold shares to cover tax obligations related to vested restricted stock units.

TriSalus Life Sciences' Chief of Research, Bryan F. Cox, sold a total of 3,184 common shares across three transactions in March 2026 to cover tax withholding obligations related to vested restricted stock units.

TriSalus Life Sciences' Chief Commercial Officer, Richard Marshak, sold shares to cover tax withholding obligations related to vested restricted stock units.

TriSalus Life Sciences' Chief Regulatory Officer, Jennifer Stevens, sold common stock totaling 3,530 shares to cover tax withholding obligations related to restricted stock unit vesting.

TriSalus Life Sciences CEO Mary Szela sold common stock totaling approximately $80,000 to satisfy tax withholding obligations from RSU vesting.

TriSalus Life Sciences' Chief Financial Officer, David Patience, acquired 3,657 shares of common stock at $4.10 per share.

TriSalus Life Sciences Director Gary B. Gordon acquired 9,756 shares of common stock at $4.10 per share in a pre-planned transaction.

TriSalus Life Sciences Director William Valle reported a planned acquisition of 30,487 common shares at $4.10 each.

TriSalus Life Sciences CEO and President Mary T. Szela acquired 30,487 shares of common stock, signaling increased insider confidence.

TriSalus Life Sciences Director Michael P. Stansky acquired additional common stock directly and indirectly through an LLC on February 23, 2026, increasing his beneficial ownership to 986,830 shares.

TriSalus Life Sciences Director Michael P. Stansky was granted 92,537 stock options with an exercise price of $4.91, vesting annually over three years.

TriSalus Life Sciences' Chief of Research, Bryan F. Cox, was granted 40,000 restricted stock units and 80,000 employee stock options.

TriSalus Life Sciences' Chief of Clinical Operations, Jodi Devlin, was granted 50,000 restricted stock units and 100,000 employee stock options.

TriSalus Life Sciences CEO Mary T. Szela increased her beneficial ownership through performance stock units, restricted stock units, and stock options.